These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21745686)

  • 1. Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2.
    Chen C; Sun SR; Gong YP; Qi CB; Peng CW; Yang XQ; Liu SP; Peng J; Zhu S; Hu MB; Pang DW; Li Y
    Biomaterials; 2011 Oct; 32(30):7592-9. PubMed ID: 21745686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.
    Chen C; Xia HS; Gong YP; Peng J; Peng CW; Hu MB; Zhu XB; Pang DW; Sun SR; Li Y
    Biomaterials; 2010 Nov; 31(33):8818-25. PubMed ID: 20723971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity.
    Chen C; Peng J; Xia H; Wu Q; Zeng L; Xu H; Tang H; Zhang Z; Zhu X; Pang D; Li Y
    Nanotechnology; 2010 Mar; 21(9):095101. PubMed ID: 20110584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer.
    Chen C; Peng J; Xia HS; Yang GF; Wu QS; Chen LD; Zeng LB; Zhang ZL; Pang DW; Li Y
    Biomaterials; 2009 May; 30(15):2912-8. PubMed ID: 19251316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
    Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
    Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
    Glück S; Yip AY; Ng EL
    Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S17-22. PubMed ID: 22316427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change?
    Raica M; Jung I; Cîmpean AM; Suciu C; Mureşan AM
    Rom J Morphol Embryol; 2009; 50(1):5-13. PubMed ID: 19221640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3).
    Nassar A; Cohen C; Siddiqui M
    Diagn Cytopathol; 2009 Dec; 37(12):865-70. PubMed ID: 19530101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and genetic markers in the local-regional management of breast cancer.
    Haffty BG
    Semin Radiat Oncol; 2002 Oct; 12(4):329-40. PubMed ID: 12382191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantum dots-based double-color imaging of HER2 positive breast cancer invasion.
    Liu XL; Peng CW; Chen C; Yang XQ; Hu MB; Xia HS; Liu SP; Pang DW; Li Y
    Biochem Biophys Res Commun; 2011 Jun; 409(3):577-82. PubMed ID: 21609713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.
    Kumaki N; Umemura S; Tang X; Saito Y; Suzuki Y; Tokuda Y
    Breast Cancer; 2011 Apr; 18(2):98-102. PubMed ID: 21290265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.